Rheuma und Impfen

Patienten mit rheumatischen Erkrankungen sind durch Infektionen besonders gefährdet. Impfungen sind geeignet, dieses Risiko zu vermindern. Aktuelle Empfehlungen nationaler (STIKO und Wagner et al.) sowie internationaler Gremien (EULAR) stellen eine Basis für die sichere und effektive Anwendung von Impfungen dar. Wichtige neue Entwicklungen, wie die sequenzielle Impfung gegen Pneumokokken oder die Zulassung eines Impfstoffs gegen Herpes Zoster, verbessern die Möglichkeiten eines effektiven Infektionsschutzes. Besonders zu beachten sind die aktuellen Empfehlungen zur Anwendung von Lebendimpfstoffen wie der MMR-Impfung bei Patienten unter immunsuppressiver Therapie.

Publication History

Article published online:
16 June 2021

• Literatur

• 1 Furer V, Rondaan C, Heijstek MW. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020; 79: 39-52
• 2 Robert-Koch-Institut. Epidemiologisches Bulletin 34/2019 (22.8.2019). https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2019/Ausgaben/34_19.pdf;jsessionid=8CA69B8290D1B093C3E008D87944B425.internet081?__blob=publicationFile Stand: 15.8.2020
• 3 Wagner N, Assmus F, Arendt G. et al. Impfen bei Immundefizienz. Bundesgesundheitsbl 2019; 62: 494-515.
• 4 Rondaan C, Furer V, Heijstek MW. et al. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open 2019; 5: e001035
• 5 Kobashigawa T, Nakajima A, Taniguchi A. et al. Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort. Scand J Rheumatol 2013; 42: 445-450
• 6 Izumi Y, Akazawa M, Akeda Y. et al. The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial. Arthritis Res Ther 2017; 19: 15
• 7 Walker UA, Hoffman HM, Williams R. et al. Brief Report Severe Inflammation Following Vaccination Against Streptococcus pneumoniae in Patients With Cryopyrin-Associate Syndromes. Arthritis Rheumatol 2016; 68: 516-520
• 8 Huang Y, Wang H, Tam WWS. Is rheumatoid arthritis associated with reduced immunogenicity of the influenza vaccination? A systematic review and meta-analysis. Curr Med Res Opin 2017; 33: 1901-1908
• 9 Puges M, Biscay P, Barnetche T. et al. Immunogenicity and impaction disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis. Rheumatology 2016; 55: 1664-1672
• 10 Holvast A, van Assen S, de Haan A. et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology 2009; 248: 1294-1249
• 11 Kaine JL, Kivitz AJ, Birbara C. et al. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007; 34: 272-279
• 12 Park JK, Lee YJ, Shin K. et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 2018; 277: 898-904
• 13 Pleguezuelos O, James E, Fernandez A. et al. Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study. NPJ Vaccines 2020; 5: 22
• 14 Brisson M, Kim JJ, Canfell K. et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lowermiddle-income countries. Lancet 2020; 395: 575-590
• 15 Mok CC, Ho LY, To CH. Long-Term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus. Vaccine 2018; 36: 3301-3307
• 16 Niehues T, Bogdan C, Hecht J. et al. Impfen bei Immundefizienz. Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen (I) Grundlagenpapier. Bundesgesundheitsbl 2017; 60: 674-684
• 17 Lindsey NP, Schroeder BA, Miller ER. et al. Adverse event reports following yellow fever vaccination. Vaccine 2008; 26: 6077-6082